Objective: To review the current practices for metastatic non–small cell lung cancer (NSCLC)
management and highlight the latest progress. Data Sources: A literature review using …

… KRAS mutated lung cancers appear especially resistant to inhibitory strategies. … should
be developed to inhibit the aggressive KRASG12V mutant lung cancer phenotype. …

… The number of lung cancer-related deaths in 2018 was estimated to be 1.8 million, which …
one-fifth of all cancer-related deaths (Bray et al., 2018). Non-small cell lung cancer (NSCLC) is …

… While preclinical data indicate that complement inhibitors may represent a novel therapeutic
strategy for treating cancer in general and lung cancer in particular, there are currently no …

… both of lung cancer in mono-and combination therapies. However, … lung cancer. Here, it
summarizes the main molecular mechanisms associated with platinum resistance in lung cancer …

… showed a new therapeutic strategy for cancer therapy based on … in lung cancer, and discuss
a new miRNA-based therapeutic … miRNA-based therapeutic strategy to manage lung cancer. …

… lung cancer, such as oncogene dependency, DNA damage response, angiogenesis, and
cellular plasticity arising from presence of cancer … novel therapeutic agents for lung cancer that …

… In many cancers, including non-small cell lung cancer (NSCLC), tumor angiogenesis
pathways have been identified as important therapeutic targets. Angiogenesis is essential in the …

… In conclusion, the therapeutic strategy for treating postoperative recurrence in patients with
NSCLC should be considered according to the mode of first recurrence. In this way, proper …

… the role of glutamine metabolism in lung cancer. Because lung cancer is the leading cause
of cancer death with limited curative treatment options, we focus on the potential therapeutic …